Scalper1 News
Biotech Agios Pharmaceuticals (AGIO) on Friday reported positive early-stage data on a blood-cancer drug it’s developing with Celgene (CELG), but its stock tumbled more than 10% as the response rate seemed to miss investor expectations. Agios said that out of 158 patients with acute myeloid leukemia (AML) and other advanced blood cancers taking AG-221, the response rate (tumor shrinkage) was 40%, while 16% went into complete remission. Agios also Scalper1 News
Scalper1 News